Skip to content
IRTM Group
Taumex Therapeutics

Taumex: Revolutionising Alzheimer's treatment

Advanced molecular therapies that target tau proteins, bringing new hope to patients and changing how Alzheimer's disease is treated worldwide.

01

Breaking through Alzheimer's barriers

Alzheimer's affects more than 55 million people and costs the global economy over $1 trillion a year. Most current therapies only ease symptoms or target amyloid-beta, with limited long-term benefit. Taumex is taking a different path.

02

A new approach

Co-founded in the United States by IRTM Chairman Ali Taraghijah and neuroscientist Professor Koorosh Shahpasand, Taumex is developing a proprietary antibody, pT231-tau, designed to target the pathological tau proteins now recognised as key drivers of the disease.

03

Precision medicine

The therapy is disease-modifying. pT231-tau neutralises one of the earliest and most toxic forms of hyperphosphorylated tau, which collapses the microtubule structures neurons depend on, aiming to stop the disease, not just slow it.

04

Clinical progress

Pre-clinical studies showed the antibody preventing cognitive decline. Phase 1 trials confirmed safety and bioactivity with no severe adverse effects. A Phase 2a trial enrolling 60 patients is now under way in certified hospitals in Erbil, Iraq.

05

Built to international standards

Taumex works with an experienced contract research organisation to ensure professional oversight, and the antibody is manufactured under Good Manufacturing Practice (GMP), ready for broader clinical use.

06

Redefining hope

As populations age, the burden of Alzheimer's will keep rising. A therapy that addresses the core mechanism of neurodegeneration would transform outcomes for patients, families and health systems.

Talk to the Taumex team
Products

More from IRTM

Speak to IRTM

Let's build what's next, together.

Tell us what you need. Our investment, trading and technology teams will get back to you within one business day.